Introducing our principal faculty
Sinéad Whitty is Co-Founder of FCD and Director of Learning at FCD.
She is also Head of Training, Teaching and Career Development at The Global Health Network.
Previously she was the Pedagogy Coordinator at the Department of Medicine in Karolinska Institutet where she was responsible for the design, development and delivery of a suite of online, post-graduate capacity development programs in Pharmacometrics, Bioequivalence, Meta-analysis and Clinical Trial Management.
With a background in Leadership and Modern Languages, Sinéad has over twenty years’ experience teaching face to face, blended and online. She is an advocate for technology that supports good teaching and learning practices. Sinéad’s programs are designed to align teaching, learning and the practical skills required to develop personal capacity. The programs are student-centered, outcomes-based and rooted in constructivism. Her research interests include universal design, learner support and virtual teamwork.
Dr Tim Grant
Dr Tim Grant is a graduate of the University of Wisconsin-Madison with a PhD in Educational Psychology and an MSc in Biostatistics. He has over 20 years experience designing and analysing clinical trials most of which is for the pharmaceutical industry. In addition to experience with randomized controlled trials, Tim has also worked on various health research studies which includes, survival analysis, meta-analysis, and epidemiological studies. He regularly teaches as an external lecturer at Trinity College Dublin and a Senior External Lecturer at Karolinska Institutet.. He is currently working in the area of health economics providing statistical support to decision making process.
Dr Luther Gwaza
Dr Luther Gwaza is an experienced regulator, development practitioner, pharmaceutical public health specialist and researcher. Luther is a qualified pharmacist with a PhD in Pharmaceutical Policy and Regulation with extensive knowledge and experience in the regulation of medicines, vaccines and other health products at a national and international level.
From various short and long term assignments in regulatory cooperation and systems strengthening at a continental level, he has in-depth knowledge of regulatory systems, delivering results in challenging and complex environments with regulators, the pharmaceutical industry and international partners. He is one of the persons involved in the foundation and ongoing development of the ZAZIBONA initiative in Southern Africa.
Professor John A. Clendenin
Professor John A. Clendenin is Distinguished Visiting Professor at IE Business School and previously Senior Associate Dean of Post Graduate Studies at IE. Clendenin is a Senior Fellow at FCD with whom he works on a number of programs, and lectures on Leadership and Ethics in our Master and Post Graduate Diploma programs.
Professor Clendenin capacity development ethos draws on over 50 years of teaching in some of the world leading universities, including Harvard Business School where was a Senior Lecturer. His teaching is also informed by his 23 years as a Lieutenent Colonal in the United States Marine Corp, 15 years as Director of the. Multinational Development Center at Xerox where he became internationally recognised as a leading ‘change agent’ and international productivity expert.
Professor Clendenin was a team member of the silver medal winning U.S.A. 1984 Olympic Modern Pentathlon Team. Since then he has worked with Olympic teams, professional athletes, educators and business professionals in the area of performance management, motivation and goal setting. He holds membership in the International Society of Sport Psychology and the New York Academy of Sciences.
Dr Gabriela Zepeda Orozco
Dr Gabriela Zepeda Orozco has over 20 years of clinical practice supporting families and children to continue a healthy physical and emotional development. Gabriela was an investigator for phase III studies with vaccines, antibiotics and antimycotic drugs. She supported the implementation of the GCP quality system in the CPO of Novartis Mexico. She is a GCP certified trainer who has attended over 18 GCP, PV, POP, Compliance and GMP audits. She has supported the implementation of local phase II-IV studies from different Medical Affairs roles.
In addition, Gabriela has over 12 year’s experience working in the pharmaceutical industry as Medical Therapeutic Area Head of the Cardiovascular and metabolism group, Field Medical Excellence Manager/MSL Manager, Medical Information Manager, CPO Development Quality Assurance Manager, Medical GXP Training Manager, as well as Medical Scientific Liaison (MSL) in Diabetes and Hypertension.
Gabriela was a Sr. External Lecturer at Karolinska Institutet and the National Institute of Pediatrics. She has been an invited lecturer to universities, hospitals and congresses on diverse pediatric and infectious diseases topics.
Dr Pol Vendenbroucke
Dr Pol Vendenbroucke Pfizer Chief Medical Officer of the Hospital Business Unit. D Vandenbroucke’s career has been dedicated to Clinical Development, Medical Affairs, and Marketing in the U.S., Europe, Asia, and Latin America. Before his current position, he was responsible for Medical Strategy for Pfizer Inc. and for Medical Affairs of Pfizer’s Essential Health portfolio in North America.
He previously also led the Clinical Development of all Pfizer compounds in Asia, Central/Eastern Europe, Latin America, and Africa-Middle East and of Pfizer’s Established Products globally. He was also responsible for developing compounds specifically for diseases of the developing world, such as malaria and river blindness.
Dr. Vandenbroucke serves on the Board of AFAR and BIO Ventures for Global Health. He is a member of the Advisory Boards of the Steve Biko Centre for Bioethics, University of the Witwatersrand-Johannesburg, the Canadian Institutes of Health Research, and the Keck Graduate Institute, Claremont, CA. He also is a Fellow of the Faculty of Pharmaceutical Medicine of the Royal Colleges of Medicine of the United Kingdom.
Before joining Pfizer, Dr. Vandenbroucke was Medical Director, Sterling-Winthrop International, Cardiovascular and CNS Disease Manager at Novartis Mexico, and Professor at the Instituto Tecnológico Autónomo de México (ITAM).
He holds a Medical Degree from the Catholic University of Louvain (Belgium), an MBA degree from the Instituto Tecnológico Autónomo de México (ITAM), and an MSc (First Honors) from Hibernia College (Ireland). He is a member of the Pfizer Latino PCC Leadership Team. He is fluent in Dutch, Spanish, English, French, German and basic Japanese.
Professor Florence Oloo
Professor Florence Oloo is Director of the Centre for Research in Therapeuitc Sciences (CREATES) at Strathmore University, Kenya. Professor Oloo received her Bachelor of Science degree in Chemistry from the University of Nairobi, followed by a Master’s of Science degree in Chemistry from the University of Ibadan in Nigeria her and doctorate in Chemistry from Jomo Kenyatta University of Agriculture and Technology. Professor Oloo also pursues academic interests in professional ethics and rural and women’s issues. She spent her sabbatical year in 2011, at the Council for Scientific and Industry Research (CSIR), South Africa, within the drug delivery group with a special interest in Encapsulation of Malaria drugs while undertaking lecturing as an Associate Professor in Chemistry, at the Technical University of Kenya, (TUK)
Prof Oloo is the Platform Coordinator of the Centre for Research in Therapeutic Sciences and the Director of Global and Community Engagement at the Technical University of Kenya (TUK)
Professor Manuel García Goñi
Professor Manuel García Goñi is Professor of Applied Economics at the Faculty of Economic and Business Sciences at Complutense University, Madrid, where he was Vice Dean of International Relations from 2015 to 2019. He has a Doctorate in Economics and a Masters in Political Economy from Boston University with a specialty in Health Economics and Industrial Economics. He has been Visiting Scholar at Columbia, Visiting Fellow at the Australian National University (Canberra, Australia).
Manuel has published scientific articles in peer-reviewed journals such as Value in Health, Health Economics, Health Policy, Research Policy, European Journal of Health Economics, International Journal of Equity in Health and Ageing, among others. Occasionally, international institutions such as the American TPG International Health Academy (United States) or the Ministry of Health and Social Protection of Colombia have requested his input as a world leading expert in his field. His research has been funded by prestigious institutions in various countries, such as the European Commission, the International Monetary Fund (IMF), the Inter-American Development Bank (IDB), the Centers for Medicare; Medicaid Services (United States), the Mitchell Institute for Health and Education Policy (Australia), and the Institute of Fiscal Studies and the Ramón Areces Foundation in Spain.
Jeremy Whitty is co-founder of FCD and Director of Development at The Global Health Network at Oxford University, which has delivered over 2.2 million online courses to 400,000 members. From January 2020 to October 2021 TGHN delivered over 150 webinars and workshops to 23,000 attendees.
Jeremy is co-director of the MSc in Pharmacy Administration and Policy Regulation at the University of the Western Cape and course director of the PG Certificate in Clinical Research Operations with the Institute for Global Health at the University of Siena.
He co-founded FCD in 2016 to help build capacity in health sciences, especially in clinical operations. He is currently working on a large capacity development program with organizations based in the US, Europe and Africa.
Previously, Jeremy was Professor of Operations at Instituto de Empressa, Madrid, he was director of online programs at the Dept. of Medicine at Karolinska Institutet and program director of an MSc in Pharmaceutical Medicine. He has worked on several EU IMI projects and working in industry he was a global lead on change management and operational excellence programs, a senior scientist and a principal engineer.